Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT05238649
Recruitment Status : Active, not recruiting
First Posted : February 14, 2022
Last Update Posted : March 29, 2022
Information provided by (Responsible Party):
Livzon Pharmaceutical Group Inc.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : November 30, 2022
Estimated Study Completion Date : January 28, 2023